You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Acquisition of psoriasis product deepens Astellas’ Commitment to Dermatology franchise Deerfield, IL and Cambridge, MA, April 3, 2006 – Astellas Pharma US, Inc. and Biogen Idec Inc. (NASDAQ:...
Heart indication for Prograf reinforces a 20-year commitment to research and development in transplantation DEERFIELD, IL, APRIL 1, 2006 – The Food and Drug Administration (FDA) has granted...
Vancouver, Canada and Deerfield, Illinois, USA, March 31, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. today announced...
MELVILLE, N.Y., Feb 01, 2006 -- OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) today announced fourth quarter international sales for its flagship product, Tarceva® (erlotinib). Net international sales...
Recently, new information was added to the US labeling for the class of topical calcineurin inhibitors, or TCIs, which includes Protopic® (tacrolimus) Ointment and pimecrolimus cream. The new...
Follow U.S. news
